Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases

• DOI: 10.1016/j.jgar.2022.06.008
• Publication Date: 2022-06-15T06:53:15Z
• Authors: Madhvi Ahuja; Itu Singh; Mallika Lavania; Vinay Kumar Pathak; Joydeepa Darlong; Ravindra P Turankar; S. Hembrom; Shoor Veer Singh; Utpal Sengupta
• Keywords: Dapsone; rpoB; Mycobacterium leprae; Sanger sequencing

Purulia is one of the high-endemic districts for leprosy in West Bengal (the eastern part India). The annual new case detection rate (ANCDR) 6.04/100000 (DGHS 2019-20). Our earlier report provided evidence secondary drug resistance relapse cases leprosy. aim current study was to observe primary patterns dapsone, rifampicin, and ofloxacin amongst patients from Purulia, order better understand emergence these drugs.In present study, slit-skin smear samples were collected 145 newly diagnosed Leprosy Mission (TLM) hospital between 2017 2018. DNA extracted Mycobacterium leprae genome analyzed genes associated with by polymerase chain reaction (PCR), followed Sanger sequencing. Wild-type strain (Thai-53) mouse footpad-derived drug-resistant (Z-4) used as reference strains.Of cases, 25 showed mutations (as described World Health Organization, rpoB, folP, gyrA, respectively) through Of 16 ofloxacin, two combinations four a mutation only rifampicin dapsone.Results this indicated antileprosy drugs As alternate treatment rifampicin-resistant indicates that ofloxacin-resistant M. strains are actively circulating endemic region (i.e., Bengal), posing challenges effective cases.